Ruxolitinib Safety and Feasibility in NHGGs: Final Toxicity Report Brain 2 Mins Read1 The results of the CRUX study, which focused on the safety and feasibility of the JAK stat inhibitor Ruxolitinib in…
Ibrutinib EQULIBRIUM Trial: Final Trial Report in nHGGs Brain 3 Mins Read1 At the (ASCO) 2023 conference, Dr. Manmeet Singh Ahluwalla discussed, researchers presented the final trial report on a phase 1…
